The development of autologous bone marrow mesenchymal stem cells for treatment of cerebral infarction and spinal cord injury are under clinical investigation or in phase II, and culture automation is under development. Nipro hopes to apply for approval after 4 or 5 years.

Nipro press release, Nov. 20, 2014